

CELLTECH GROUP PLC  
Form 6-K  
May 23, 2003

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Report of Foreign Private Issuer**

**Pursuant to Rule 13a - 16 or 15d - 16 of**

**the Securities Exchange Act of 1934**

For the month of **May, 2003**

Commission File Number: **1-10817**

**CELLTECH GROUP PLC**

(Translation of registrant's name into English)

**208 Bath Road, Slough, Berkshire SL1 3WE ENGLAND**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

(If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_).

Enclosure: Holding(s) in Company released 23 May, 2003

## SCHEDULE 10

### NOTIFICATION OF MAJOR INTERESTS IN SHARES

1. Name of company

Celltech Group plc

2. Name of shareholder having a major interest

The Capital Group Companies, Inc. on behalf of its affiliates, including Capital Research and Management Company, Capital International S.A., Capital International, Inc., Capital Guardian Trust Company and Capital International Limited

3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age of 18

As in 2 above

4. Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them

Bank of New York Nominees	34,100
Chase Nominees Limited	1,493,400
Citibank London	106,100
Nortrust Nominees	908,400
Mellon Nominees (UK) Limited	80,600
State Street Nominees Limited	306,700
Bank of New York Nominees	5,619,999
Northern Trust	1,454,502
Chase Nominees Limited	3,524,463
Midland Bank plc	168,500

Edgar Filing: CELLTECH GROUP PLC - Form 6-K

Bankers Trust	2,328,400
Barclays bank	60,000
Citibank London	53,000
Morgan Guaranty	324,300
Nortrust Nominees	2,710,306
State Street Bank & Trust Co	179,600
Deutsche Bank AG	904,300
HSBC Bank plc	1,222,000
Mellon Bank NA	230,300
Northern Trust AVFC	196,436
KAS UK	64,810
Mellon Nominees (UK) Limited	63,500
Bank One London	103,200
State Street Nominees Limited	50,000
Bank of New York Nominees	82,000
Chase Nominees Limited	996,900
Midland Bank plc	19,500
Barclays Bank	80,000
Royal Bank of Scotland	1,125,100
State Street Bank & Trust Co	80,400
Lloyds Bank	86,500
RBSTB Nominees Ltd	113,900
Citibank NA	17,600
HSBC Bank plc	281,800
State Street Nominees Limited	579,959
Bank of New York Nominees	138,400
Chase Nominees Limited	759,000
Citibank London	10,000
Nortrust Nominees	273,000
State Street Bank & Trust Co	14,999

Citibank NA	98,400
Chase Manhattan Nominee Ltd	5,300
HSBC Bank plc	54,400
State Street Nominees Limited	815,838

5. Number of shares / amount of stock acquired

1,078,738 (since last notification)

6. Percentage of issued class

0.38%

7. Number of shares / amount of stock disposed

N/a

8. Percentage of issued class

N/a

9. Class of security

Ordinary 50p Shares

10. Date of transaction

21 May 2003

11. Date company informed

23 May 2003

12. Total holding following this notification

27,819,912

13. Total percentage holding of issued class following this notification

10.02%

14. Any additional information

-

15. Name of contact and telephone number for queries

Anita Dowling (01753) 777106

16. Name and signature of authorised company official responsible for making this notification

J A D Slater

Date of notification

23 May 2003

The FSA does not give any express or implied warranty as to the accuracy of this document or material and does not accept any liability for error or omission. The FSA is not liable for any damages (including, without limitation, damages for loss of business or loss of profits) arising in contract, tort or otherwise from the use of or inability to use this document, or any material contained in it, or from any action or decision taken as a result of using this document or any such material.

END

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PLC

CELLTECH GROUP

(Registrant)

ALLEN

By: /s/ PETER

Officer

Peter Allen  
Chief Financial

Dated: 23 May, 2003